Union Square Ventures (USV) has announced its investment in Humane Genomics, a biotech company focused on developing programmable synthetic viruses for cancer treatment. This investment marks USV's first in the biotech sector, as they aim to support innovative solutions in healthcare. Humane Genomics has successfully secured $6.8 million in seed financing, with USV leading the round. The company's digital design platform allows for rapid development of synthetic biology applications, which could significantly advance cancer therapies. Additional reports indicate that USV is actively involved in the biotech space, emphasizing the potential of programmable biology in medical advancements.